Clinical Trials Browser

Phase 2/3 × Hematologic Neoplasms × peginterferon alfa-2b × Clear all

NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Phase 2/3 Completed

Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms